Medtronic plc · NYSE (us_market)
Healthcare · Medical Devices · Ireland
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2023-07-26$90.40 RISE2023-10-27$69.43 PEAK2024-01-12$87.42 170d | -23.2% 93d | Missed | Missed | — | — | +25.9% 77d | Missed |
DROP2022-08-16$95.31 RISE2022-11-28$76.13 PEAK2023-02-02$87.58 170d | -20.1% 104d | Missed | Missed | — | — | +15.0% 66d | Missed |
DROP2020-02-20$113.86 RISE2020-06-26$88.77 PEAK2020-09-02$108.78 195d | -22.0% 127d | 2020-03-18 $74.54 | 2020-08-26 $104.08 | 67Deep Value | 45Watch | +22.5% 68d | +39.6% Held 161d |
DROP2020-02-06$121.30 RISE2020-03-23$72.92 PEAK2020-04-17$103.33 71d | -39.9% 46d | 2020-03-18 $74.54 | 2020-04-17 $103.33 | 67Deep Value | 48Watch | +41.7% 25d | +38.6% Held 30d |
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1%.
Medtronic plc (NYSE:MDT) is one of the best medical technology stocks to buy right now. On May 21, Goldman Sachs reinstated coverage of Medtronic plc (NYSE:MDT) with a Neutral rating and an $84 price target. The firm noted that Medtronic stock’s sharp pullback has brought its risk/reward profile to a roughly balanced position. Goldman sees […]
Medtronic (MDT) heads into its fourth quarter fiscal 2026 earnings on June 3 with several moving pieces, including completed and planned acquisitions, new FDA clearances, and a voluntary Class II software recall. See our latest analysis for Medtronic. The share price has been under pressure ahead of the earnings release, with a 30 day share price return down about 6.9% and a 90 day share price return down almost 19.7%, even though the 3 year total shareholder return is still slightly...
The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.
Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, Medtronic (MDT) stood at $77.6, denoting a -1.27% move from the preceding trading day.
ISRG is widening its robotic surgery lead with faster growth, rising procedures and a recurring revenue model as Medtronic builds Hugo.
ISRG is widening its robotic surgery lead with faster growth, rising procedures and a recurring revenue model as Medtronic builds Hugo.
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Heart conditions can impact anyone, anywhere. NORTHAMPTON, MA / ACCESS Newswire / May 26, 2026 / Heart conditions can impact anyone, anywhere, and often without warning. Fifty-nine-year-old Ana Florencio experienced this first-hand when what began ...
Medtronic plc (NYSE:MDT) is one of the best robotic surgery stocks to buy. Medtronic plc (NYSE:MDT) announced on May 20 its intention to acquire SPR Therapeutics, Inc. (SPR), which is a privately held medical technology company that holds a leading position in temporary, percutaneous peripheral nerve stimulation therapies for chronic pain management. Management stated that the […]
Medtronic plc (NYSE:MDT) is one of the best robotic surgery stocks to buy. Medtronic plc (NYSE:MDT) announced on May 20 its intention to acquire SPR Therapeutics, Inc. (SPR), which is a privately held medical technology company that holds a leading position in temporary, percutaneous peripheral nerve stimulation therapies for chronic pain management. Management stated that the […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MDT | -7.74% | -24.76% | -23.16% | -11.05% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -10.71% | -19.05% | -19.72% | -23.74% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 61.74M | $5.39B | 0.19% | Unchanged | 2026-03-31 |
| CapResearch | fundamental | 41.93M | $3.63B | 0.56% | Added+21.3% | 2026-03-31 |
| Wellington | fundamental | 7.53M | $652.09M | 0.12% | Trimmed-43.7% | 2026-03-31 |
| FidelityFMR | fundamental | 2.55M | $221.09M | 0.01% | Added+1.5% | 2026-03-31 |
| DEShaw | quant | 894.6K | $77.52M | 0.05% | Trimmed-9.8% | 2026-03-31 |
| TwoSigma | quant | 605.6K | $52.47M | 0.04% | Trimmed-37.5% | 2026-03-31 |
| Bridgewater | macro | 255.2K | $22.12M | 0.10% | Trimmed-9.6% | 2026-03-31 |
| TRowePrice | fundamental | 5.88M | $509.88K | 0.06% | Added+1.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-28 | Blomquist Denise L. | Chief Accounting Officer | M Option exercise(deriv) | 1,621 | — | +$0 |
| 2026-05-28 | Blomquist Denise L. | Chief Accounting Officer | M Option exercise | 1,712 | — | +$0 |
| 2026-05-28 | KIIL HARRY SKIP | EVP & President Cardiovascular | M Option exercise(deriv) | 14,517 | — | +$0 |
| 2026-05-28 | KIIL HARRY SKIP | EVP & President Cardiovascular | M Option exercise | 15,195 | — | +$0 |
| 2026-05-28 | Marinaro Michael | EVP, Pres MedSurg and Americas | M Option exercise(deriv) | 17,093 | — | +$0 |
| 2026-05-28 | Marinaro Michael | EVP, Pres MedSurg and Americas | M Option exercise | 18,994 | — | +$0 |
| 2026-05-28 | Martha Geoffrey | Chairman and CEO | M Option exercise(deriv) | 85,461 | — | +$0 |
| 2026-05-28 | Martha Geoffrey | Chairman and CEO | M Option exercise | 94,963 | — | +$0 |
| 2026-05-28 | Wall Brett A. | EVP & Pres Neuroscience | M Option exercise(deriv) | 24,214 | — | +$0 |
| 2026-05-28 | Wall Brett A. | EVP & Pres Neuroscience | M Option exercise | 26,907 | — | +$0 |
| 2026-05-28 | Walter Matthew R. | SVP, Chief HR Officer | M Option exercise(deriv) | 8,449 | — | +$0 |
| 2026-05-28 | Walter Matthew R. | SVP, Chief HR Officer | M Option exercise | 9,149 | — | +$0 |
| 2026-05-04 | Walter Matthew R. | SVP, Chief HR Officer | F Tax withholding | 35 | $80.00 | −$2.8K |
| 2026-04-29 | ARNOLD CRAIG | Director | F Tax withholding | 207 | $81.90 | −$17.0K |
| 2026-04-29 | ARNOLD CRAIG | Director | A Grant / award | 2,111 | — | +$0 |
| 2026-04-29 | DONNELLY SCOTT C | Director | F Tax withholding | 207 | $81.90 | −$17.0K |
| 2026-04-29 | DONNELLY SCOTT C | Director | A Grant / award | 2,111 | — | +$0 |
| 2026-04-29 | Fonseca Lidia | Director | F Tax withholding | 207 | $81.90 | −$17.0K |
| 2026-04-29 | Fonseca Lidia | Director | A Grant / award | 2,111 | — | +$0 |
| 2026-04-29 | Groetelaars John P | Director | A Grant / award | 1,444 | — | +$0 |
| 2026-04-29 | HOGAN RANDALL J | Director | F Tax withholding | 207 | $81.90 | −$17.0K |
| 2026-04-29 | HOGAN RANDALL J | Director | A Grant / award | 2,111 | — | +$0 |
| 2026-04-29 | Jellison William R | Director | A Grant / award | 1,444 | — | +$0 |
| 2026-04-29 | Lee Joon Sup | Director | A Grant / award | 1,803 | — | +$0 |
| 2026-04-29 | Lewis Gregory P | Director | F Tax withholding | 207 | $81.90 | −$17.0K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-03upcoming | 1.55 | — | — |
| 2026-02-17 | 1.01 | 0.89 | -11.92% |
| 2025-11-18 | 1.31 | 1.36 | +3.49% |
| 2025-08-19 | 1.23 | 1.26 | +2.54% |
| 2025-05-21 | 1.58 | 1.62 | +2.69% |
| 2025-02-18 | 1.36 | 1.39 | +2.24% |
| 2024-11-19 | 1.25 | 1.26 | +0.85% |
| 2024-08-20 | 1.20 | 1.23 | +2.65% |
| 2024-05-23 | 1.45 | 1.46 | +0.70% |
| 2024-02-20 | 1.26 | 1.30 | +3.06% |
| 2023-11-21 | 1.18 | 1.25 | +5.82% |
| 2023-08-22 | 1.11 | 1.20 | +8.18% |
| 2023-05-25 | 1.55 | 1.57 | +1.01% |
| 2023-02-21 | 1.27 | 1.30 | +2.40% |
| 2022-11-22 | 1.28 | 1.30 | +1.79% |
| 2022-08-23 | 1.12 | 1.13 | +1.02% |